FDA is still struggling with a lack of inspectors, but doesn’t have a plan, watchdog finds
A key reason positions haven’t been filled is that they require travel that ranges from 25% to 75% of the time.
Related Articles
Neurogene and the race to the bottom of gene therapy
At Neurogene, the developer of a gene therapy for Rett syndrome, expediency seems to be the priority, @adamfeuerstein writes.
Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen’s lead obesity candidate, the company defended its drug and has asked the journal to issue…
Every Lab Can Go Greener With These Key Steps – MedCity News
By conducting audits, embracing new technologies and switching products, labs can dramatically reduce plastic waste without sacrificing life-saving discoveries.
Vertex’s upcoming sciatica trial readout is a high-stakes moment in its quest to quell pain
.@VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.
Pharmalittle: We’re reading about a Merck deal, GSK cancer drug data, and more
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company
Automated Identification of Key Steps in Robotic-Assisted Radical Prostatectomy Using Artificial Intelligence – Abhinav Khanna
Ruchika Talwar interviews Abhinav Khanna about his work on AI and prostate cancer surgery. Dr. Khanna discusses his team’s development of an AI platform that…
IMPLEMENT Study: Addressing the Underutilization of Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer – Stacy Loeb
Zach Klaassen and Stacy Loeb discuss the IMPLEMENT Study, which investigates the underutilization of treatment intensification in metastatic hormone-sensitive prostate cancer. Despite guidelines recommending this…
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
Merck is licensing a new cancer drug from a Chinese firm, entering a buzzy field of oncology.
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
Merck is licensing a new cancer drug from a Chinese firm, entering a buzzy field of oncology.
Personalizing Salvage Radiation and Hormone Therapy for Biochemical Recurrence – Daniel Spratt
Alicia Morgans speaks with Dan Spratt about his presentation on the management of biochemical recurrence in prostate cancer post-radical prostatectomy. Dr. Spratt explains the considerations…